258 results found (page 5 of 18)
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-e…

On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated…